Clinical relevance of therapeutic drug monitoring for amikacin and gentamicin

• Autor(a) principal: Steffens, Nadine Arnold
• Data de Publicação: 2023
• Outros Autores: Petreceli, Rodrigo Redel, Vida, Roselaine Lima da, Corrêa, Gabrielle Lima, Zimmermann, Estevan Sonego, Brucker, Natália
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Saúde (Santa Maria)
• Texto Completo: https://periodicos.ufsm.br/revistasaude/article/view/74576
• topic: Antibiotics; Aminoglycosides; Infection; Adverse effects; Aminoglicosídeos; Efeitos adversos; Infecção; Antibióticos

Aminoglycoside antibiotics (AG) are widely prescribed to treat severe bacterial infections I in neonates, elderly, and critically ill patients. Considering the global increase in antimicrobial resistance, it is necessary to address this problem by optimizing available resources. Therapeutical drug monitoring (TDM) allows dose individualization and assists in preventing under or overdosage-related events. In this sense, the objective of this review was to analyze scientific evidence in the literature about the clinical importance of TDM for AG, access available data about its benefits, cover the main topics and provide an overview of this practice. PubMed and Science Direct databases were searched for: “therapeutic drug monitoring” and “aminoglycosides,” limiting the search to articles published between 2015 and 2022. In total, 26 articles were included in this review. TDM seems to be especially beneficial to elderly, neonates and critically ill patients, and target concentrations and sampling times are already well established, with the most recommended target being Cmax/MIC > 8. However, knowledge and training of the involved staff are essential to implement and interpret the TDM adequately.